Adeno-associated virus (AAV) * VVector Bio

VVector Bio is a spin-out of McGill University developing cutting-edge technologies for cost-effective manufacturing of cell and gene therapies. The company specializes in advanced plasmid and cell systems leveraging functional genomics to improve AAV yields and quality by orders of magnitude compared to industry standards.

Core Capabilities:

• AAV Single Plasmid Technology (SAAVANA™): Single-plasmid transfection platform available for licensing that reduces plasmid production costs by up to 66%.
• Viral Vector Plasmids: Provides plasmids containing Rep2-Cap serotypes 2, 5, 6, 8, and 9 for AAV production; packaging plasmids and transfer vectors for 2nd and 3rd generation lentivirus vectors; FastBac system for rapid bacmid generation for baculovirus-based AAV assembly in insect cells; pAdEasy adenoviral vector system for adenovirus production in HEK-293 cells.
• Process Development & Tech Transfer: Extensive hands-on experience in process development with seamless tech transfer to GMP facilities up to 50-L scale.
• Gene Synthesis & Cloning: Can proceed with projects using only gene sequences, performing chemical synthesis and cloning into plasmid vectors with amplification to required scale.
• Viral Vector Production: Manufactures non-infectious, non-replicative AAV, lentivirus, and adenovirus vectors. AAV produced in HEK-293 cells (BSL-2); lentivirus for ex-vivo CAR-T cell therapy; adenovirus for vaccination, gene therapy, and cancer therapy applications.

Typical Project Timelines: AAV (HEK-293) ~6 weeks; Lentivirus ~6 weeks; Adenovirus ~8 weeks; AAV (insect cell system) ~8 weeks.